.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Cantor Fitzgerald
Boehringer Ingelheim
Johnson and Johnson
QuintilesIMS
McKinsey
Farmers Insurance
AstraZeneca
Teva

Generated: January 23, 2018

DrugPatentWatch Database Preview

US Patents With Foreign Priority to Patent: 09150159

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer IngelheimJENTADUETOlinagliptin; metformin hydrochlorideTABLET;ORAL201281-001Jan 30, 2012RXYesNo➤ Subscribe➤ SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
Boehringer IngelheimJENTADUETOlinagliptin; metformin hydrochlorideTABLET;ORAL201281-002Jan 30, 2012RXYesNo➤ Subscribe➤ SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
Boehringer IngelheimJENTADUETOlinagliptin; metformin hydrochlorideTABLET;ORAL201281-003Jan 30, 2012RXYesYes➤ Subscribe➤ SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
Boehringer IngelheimTRADJENTAlinagliptinTABLET;ORAL201280-001May 2, 2011RXYesYes➤ Subscribe➤ SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist